Recent investigations have focused on the overlap of GLP|GIP|GCGR activator therapies and dopaminergic neurotransmission. While GLP activators are commonly employed for treating type 2 diabetes mellitus, their unexpected consequences on reinforcement circuits, specifically governed by DA systems, are receiving considerable interest. This article pr